NEJM: Millions of people data studies have shown that four-price HPV vaccination significantly reduces the risk of immersive cervical cancer.

HPV (Human PapillomaVirus) is a type of virus that causes skin papilloma-like lesions, has been isolated more than 100 subsypes, according to the infected tissue site and symptoms are classified as low-risk and high-risk types, usually lead to warts and a variety of cancers, including cervical cancer, which is the world's second leading cause of death of women.
previous studies have shown that hpV vaccines can be effective in preventing major cancer-causing types of HPV infections, namely warts and precanceral cervical lesions that can develop into cervical cancer.
, however, no studies have been conducted to assess the effectiveness of the vaccine for the most serious type of infested cervical cancer in cervical cancer, and there is a lack of large population-based studies.
A recent study published in The New England Journal Of Medicine by a team at Karolinska University in Sweden found that getting a temply pyrethroid HPV vaccine significantly reduced a woman's risk of leaching cervical cancer, with more significant benefits before the age of 17. using the Swedish National Register of Population and Health,
researchers tracked more than 1.67 million women aged 10-30 between 2006 and 2017 and counted their four-price HPV vaccinations, as well as information on age, education, place of residence, family income, parental characteristics, and maternal history.
also counted the diagnosis of indented cervical cancer during follow-up to assess the association between HPV vaccination and risk of indented cervical cancer.
analysis of statistics from the baseline of the study population found that a total of 527,871 women were vaccinated against four-price HPV during the study period, and 83.2% of women were vaccinated before the age of 17.
19 women who were vaccinated against tyrophic HPV and 538 women who were not vaccinated were eventually diagnosed with cervical cancer.
Analysis of the cumulative incidence of cervical cancer found that by the age of 30, the cumulative incidence of cervical cancer in women not vaccinated against HPV was 94 cases per 100,000 people, and the cumulative incidence rate of vaccinated women was 47 cases per 100,000 people.
for women aged 17 to 30 who are indirectly vaccinated, the cumulative incidence rate by the age of 30 is 54 cases per 100,000 people.
women who had been vaccinated before the age of 17 had a cumulative incidence of only 4 cases per 100,000 people by the age of 28.
HPV vaccination and immersive cervical cancer incidence statistics different HPV vaccination population of the cumulative incidence of immersive cervical cancer then the researchers used Poisson regression model to assess and compare the incidence of cervical cancer in vaccinated and unvaccinated women, adjusted the covariative information, found HPV vaccination and immersion cervical Significant reductions in the risk of developing cervical cancer were associated with a 63 per cent lower overall risk of cervical cancer in women who were vaccinated against HPV than in women who were not vaccinated against HPV, with women aged 17 to 30 at half the risk of developing cervical cancer and women vaccinated before the age of 17 at a significant 88 per cent lower risk of cervical cancer.
Overall, our study shows that tyrophic HPV vaccination significantly reduces the risk of cervical cancer, especially before age 17," said Jiayao Lei, author of the study.
is the first time we have demonstrated at the population level that HPV vaccination not only prevents cellular changes that may be precancer to cervical cancer, but also prevents actual indulging cervical cancer.
"